Phathom Pharmaceuticals, Inc. announced the appointment of Frank Karbe to its Board of Directors. Mr. Karbe, who most recently served as President and Chief Financial Officer of Myovant Sciences, Inc., brings over twenty-five years of financial and life-sciences expertise to Phathom.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.35 USD | +0.19% | +0.58% | +13.36% |
09/05 | Transcript : Phathom Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
09/05 | Phathom Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.36% | 61Cr | |
+46.19% | 5.57TCr | |
-6.14% | 3.96TCr | |
+40.54% | 3.99TCr | |
-6.65% | 2.82TCr | |
+12.33% | 2.63TCr | |
-21.78% | 1.89TCr | |
-0.35% | 1.21TCr | |
+24.18% | 1.21TCr | |
+28.38% | 1.22TCr |
- Stock Market
- Equities
- PHAT Stock
- News Phathom Pharmaceuticals, Inc.
- Phathom Pharmaceuticals, Inc. Appoints Frank Karbe to its Board of Directors